Skip to main content
BIO
NYSE Industrial Applications And Services

Shareholders to Vote on Equity Plan Expansion and Dual-Class Structure Challenge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$273.6
Mkt Cap
$7.383B
52W Low
$211.43
52W High
$343.12
52W Position info
29% above low
Off High info
20% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIO sits 29% above its 52-week low of $211.43.

Summary

Bio-Rad Laboratories will hold its annual meeting to vote on increasing shares for its incentive plan and a shareholder proposal challenging its dual-class voting structure, which the board opposes.


Key Events · Corporate Governance and Compliance · BIO

  • Equity Incentive Plan Expansion

    Shareholders will vote on increasing the shares reserved for the 2017 Incentive Award Plan by 335,000 shares and extending its expiration date to March 18, 2036. This increase represents a potential dilution of approximately 1.24% based on current outstanding shares.

  • Shareholder Proposal on Dual-Class Structure

    A shareholder proposal requests that the Board take steps to enable all outstanding stock to have equal one-vote per share. The Board of Directors recommends voting AGAINST this proposal, stating that the current capital structure supports the company's long-term vision and management focus.

  • Director Elections

    Six directors are nominated for re-election, with two elected by Class A common stock holders and four by Class B common stock holders.

  • Advisory Vote on Executive Compensation

    An advisory (non-binding) vote to approve executive compensation is included on the agenda for the annual meeting.


Analysis · BIO · Industrial Applications And Services

This definitive proxy statement outlines key proposals for the upcoming annual meeting, including a notable increase in shares reserved for the incentive award plan and a contentious shareholder proposal to eliminate the dual-class capital structure. The proposed equity plan expansion could result in moderate dilution, while the board's opposition to changing the dual-class structure highlights ongoing corporate governance debates, which may be viewed negatively by some investors.

At the time of this filing, BIO was trading at $273.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $211.43 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIO - Latest Insights

BIO
May 17, 2026, 8:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $247.53
Real-time Price: $331.00 info
Change: +$83.47 (+34%) info
Market Cap: $8.903B info
BIO
Apr 30, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $280.12
Real-time Price: $331.00 info
Change: +$50.88 (+18%) info
Market Cap: $8.903B info
BIO
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $287.84
Real-time Price: $331.00 info
Change: +$43.16 (+15%) info
Market Cap: $8.903B info
BIO
Feb 19, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $271.90
Real-time Price: $331.00 info
Change: +$59.10 (+22%) info
Market Cap: $8.903B info
BIO
Feb 12, 2026, 9:50 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $255.00
Real-time Price: $331.00 info
Change: +$76.00 (+30%) info
Market Cap: $8.903B info